Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223179 | 0.79 | TSHR (0.49) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL8223139 | 0.78 | TSHR (0.48) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL14456706 | 0.78 | TSHR (0.48) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL14456744 | 0.77 | KMT2A (0.56) | KMT2AALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL14456685 | 0.75 | ALDH1A1 (0.57) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL14469623 | 0.75 | TSHR (0.48) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL8230258 | 0.75 | TSHR (0.49) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL14456705 | 0.75 | KDM4E (0.53) | KMT2AALDH1A1HPGDTSHRKDM4E | |
| SCHEMBL6994266 | 0.75 | KMT2A (0.53) | KMT2AALDH1A1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL8420393 | 0.74 | ALDH1A1 (0.44) | KMT2AALDH1A1SMN1; SMN2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | KMT2A 193/4885ALDH1A1 3184/4885SMN1; SMN2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.